Skip to content
Peptide research

Sigumir

Also known as Cartilage Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

What it is

A bioregulator peptide complex from cartilage and bone tissue, marketed for joint pain and cartilage health in osteoarthritis. The case is thin: pain relief has only low-confidence support, and mobility claims have limited observational support, while the proposed metabolic effects remain unestablished. The main risk is inconsistent manufacturing quality, with a low chance of allergic reaction to its bovine source. Not an approved drug in the US; it is marketed as a dietary supplement in Russia.

Read Full record

Studied uses & evidence

Studied uses(4)

  • Reduction of pain in osteoarthritis and osteochondrosis

    Low

    Animal osteoarthritis models show efficacy; human evidence limited to small uncontrolled observations.

  • Improved joint mobility and function

    Speculative

    Small reports describe mobility improvements during combined treatment; an isolated Sigumir effect remains unestablished.

  • Support for cartilage tissue metabolism and trophism

    Speculative

    Mechanism-based only; supporting studies involve other peptides or bone density, not this peptide.

Evidence limits

Evidence Level
Limited Evidence (better than most bioregulators)

Sigumir has two PubMed-indexed clinical studies and a detailed Institute clinical report. The main study tested 33 patients with musculoskeletal conditions against 31 controls over 30-45 day courses. The TMJ study (PMID 22708467) was larger with 62 patients and showed significant improvements. While these represent better evidence than most bioregulators, they still lack double-blind randomization and have not been replicated outside Russia.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(2)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Allergic reaction to bovine cartilage-derived peptides

    Low
  • Lack of independent quality control

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.